Results 71 to 80 of about 426,371 (334)
Molecular Oncology, EarlyView.Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon +13 more
wiley +1 more source
Cellular Responses to Cisplatin-Induced DNA Damage
Journal of Nucleic Acids, 2010 Cisplatin is one of the most effective anticancer agents widely used in the treatment of solid tumors. It is generally considered as a cytotoxic drug which kills cancer cells by damaging DNA and inhibiting DNA synthesis.
Alakananda Basu, Soumya Krishnamurthy
doaj +1 more source
Jurnal Urologi Indonesia, 2020 Objective: To evaluate the effect of metformin, cisplatin, and their combination on apoptosis of bladder cancer cells. Material & Methods: Urothelial cell lines 5637 were cultured until 80% confluence.
Arifai Lumbangaol +3 more
doaj +1 more source
Expression signatures of cisplatin- and trametinib-treated early-stage medaka melanomas [PDF]
, 2019 Small aquarium fish models provide useful systems not only for a better understanding of the molecular basis of many human diseases, but also for first-line screening to identify new drug candidates.
Boswell, William +7 more
core +2 more sources
Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin
Molecular Oncology, EarlyView.The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla +10 more
wiley +1 more source
Synthesis of Self-Assembled Nanostructured Cisplatin Using the RESS Process
PharmaceuticsBackground/Objectives: The primary goal of our research is to develop a process to prepare an aqueous dispersion of Cisplatin, an important anticancer drug, with increased solubility and storage stability.
Sudhir Kumar Sharma +5 more
doaj +1 more source
Developing a highly stable PLGA-mPEG nanoparticle loaded with cisplatin for chemotherapy of ovarian cancer. [PDF]
PLoS ONE, 2011 Cisplatin is a potent anticancer drug, but its clinical application has been limited due to its undesirable physicochemical characteristics and severe side effects.
Lihua Cheng +4 more
doaj +1 more source
Genetic and cellular sensitivity of Caenorhabditis elegans to the chemotherapeutic agent cisplatin [PDF]
, 2018 Cisplatin and derivatives are commonly used as chemotherapeutic agents. Although the cytotoxic action of cisplatin on cancer cells is very efficient, clinical oncologists need to deal with two major difficulties, namely the onset of resistance to the ...
Boxem, Mike +12 more
core +1 more source
Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition
Molecular Oncology, EarlyView.We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li +10 more
wiley +1 more source
Frontiers in Pharmacology, 2017 Cisplatin (DDP) is currently one of the most commonly used chemotherapeutic drugs for treating ovarian and lung cancer. However, resistance to cisplatin is common and it often leads to therapy failure.
Wujian Zheng +11 more
doaj +1 more source